Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093804 | 0.85 | TAAR1 (0.56) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL1263547 | 0.85 | TAAR1 (0.60) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL30000562 | 0.85 | TAAR1 (0.60) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL29459538 | 0.85 | TAAR1 (0.60) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL28364592 | 0.84 | TAAR1 (0.57) | TAAR1IDO1DAOACHEMEN1 | |
| SCHEMBL2938820 | 0.83 | CALM1 (0.57) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL30674456 | 0.83 | CALM1 (0.57) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL8085716 | 0.81 | CALM1 (0.55) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL11087087 | 0.81 | LTA4H (0.53) | TAAR1IDO1LTA4HDAOACHE | |
| SCHEMBL28137856 | 0.81 | IDH1 (0.36) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | claimed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | claimed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | claimed |
| JP-2004505014-A | — | — | 2004-02-19 | — | — | JP | claimed |
| EP-1268463-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-01-02 | — | — | EP | claimed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | claimed |
| WO-2001077097-A2 | POLYCYCLIC ARYL AND HETEROARYL SUBSTITUTED 4-PYRONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| CN-112165939-A | Combination therapy | 梅制药公司 | 2021-01-01 | — | — | CN | disclosed |
| EP-2552926-A1 | DIACYLOXYSILANE-BASED, MOISTURE-CROSSLINKABLE ETHENE POLYMERS | Wacker Chemie AG (DE) | 2013-02-06 | — | — | EP | disclosed |
| EP-2550282-A1 | PRODUCTION OF SILAOXACYCLEN | Wacker Chemie AG (DE) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011159632-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS OR DISEASES OF THE EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011120851-A1 | DIACYLOXYSILANE-BASED, MOISTURE-CROSSLINKABLE ETHENE POLYMERS | WACKER CHEMIE AG (DE) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011117072-A1 | PRODUCTION OF SILAOXACYCLEN | WACKER CHEMIE AG (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| JP-2004315789-A | CYANINE COMPOUND, OPTICAL FILTER AND OPTICAL RECORDING MATERIAL | ASAHI DENKA KOGYO KK | 2004-11-11 | — | — | JP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | TAAR1 3781/4885IDO1 553/4885LTA4H 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.